Basic Informations

C.V

Amany Abd El-Khalek Aly Azouz

PERSONAL DATA:

Career: Lecturer of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University.

Date of birth: 22 November, 1981.

Place of birth: Beni-Suef, Egypt.

Address: 258, Street no. 15, Beni-Suef El-Gedida, Beni-Suef, Egypt.

Phone numbers:

• Mobile: (+2)-01003715958
• Home: (+2)-0822122030

E-mail: amany.azoz@pharm.bsu.edu.eg

             amany_azooz@yahoo.com

             amanyazouz22@gmail.com

ACADEMIC EDUCATION:

• PhD, Faculty of Pharmacy, Beni-Suef  University (2011 - 2015).

Doctor of philosophy in Pharmaceutical Sciences, Pharmacology and Toxicology. Title of the thesis: “Possible protective effect of some vasodilators and certain anti-oxidant agent against experimentally-induced nephrotoxicity in rats”.

• MSc, Faculty of Pharmacy, Cairo University (2005 - 2010).

Master degree of Pharmaceutical Sciences, Pharmacology and Toxicology. Title of the thesis: “Pharmacological study of the possible interactions between pantoprazole and some natural products on experimentally-induced gastric ulcer in rats”.

• BSc, Faculty of Pharmacy, Cairo University (1999 - 2003).

 Bachelor degree of Pharmaceutical Sciences with a general grade of “Excellent” with Honors.

TEACHING SUBJECTS:

For Undergraduate Students:

• Pharmacology 1                    
• Pharmacology 2                   
• Clinical Pharmacology        
• Therapeutics1
• Therapeutics2                    
• Toxicology                          
• Medical Terminology         
• Biostatistics                         
• Physiology                            
• First Aid

For Postgraduate Students:                               

• Pathophysiology                   
• Clinical Pharmacology         
• Therapeutics 
• Pharmacometrics                    
• Pharmaceutical care for patients with structure or neurological disorders           (pharm D students)

POSTGRADUATE COURSES:

• Recent techniques in molecular biology workshop.
• Good clinical practice (GCP) training workshop.
• The use of technology in teaching.
• University leadership.
• Credit hour system
• Thinking skills.
• Effective communication skills.
• Effective presentation skills.
• Teaching to large numbers.
• Organization of conferences.
• International publishing.
• Advanced office (word – excel – access – power point).

PARTICIPATION IN CONFERENCES:

• Amany A. Azouz, Hany A. Omar, Amira M. Abo-youssef, Gamal A. El-sherbiny, Hekma A. Abdel-latif. "Anti-ischemic, anti-inflammatory and anti-oxidant mechanisms of sildenafil and coenzyme Q10 against renal ischemia/reperfusion injury in rats" In: Proceedings of the 1st international Conference of Faculty of Pharmacy, Beni-Suef University “Health between Nutrition and Treatment”, Beni-Suef, Egypt, 30-31August, 2015.
• A.A. Azooz, H.A. Abdel-Latif, A.A. Ein-Shoka and M.E. El-Sayed. “Protective Effects of Certain Natural Products against Pyloric Ligation/Indomethacin-Induced Gastric Ulcer in Rats”. In: Proceedings of the 2nd Scientific Conference of Faculty of Pharmacy,  Cairo University  “Quality Assurance in Pharmacy Education”, Cairo, Egypt, April 26th, 2010.

PUBLICATIONS:

Fares EM Ali, Amany A Azouz, Adel G Bakr, Amira M Abo-youssef, Ramadan AM Hemeida (2018). Hepatoprotective effects of diosmin and/or sildenafil against cholestatic liver cirrhosis: The role of Keap-1/Nrf-2 and P38-MAPK/NF-κB/iNOS signaling pathway. Food Chem Toxicol, 120:294-304.

Fares EM Ali, Adel G Bakr, Amira M Abo-youssef, Amany A Azouz, Ramadan AM Hemeida (2018). Targeting Keap-1/Nrf-2 pathway and cytoglobin as a potential protective mechanism of diosmin and pentoxifylline against cholestatic liver cirrhosis. Life Sci, 207:50-60.

Mohamed A Abdelgawad, Madlen B Labib, Waleed AM Ali, Gehan Kamel, Amany A Azouz, EL-Nahass EL-Shaymaa (2018). Design, synthesis, analgesic, anti-inflammatory activity of novel pyrazolones possessing aminosulfonyl pharmacophore as inhibitors of COX-2/5-LOX enzymes: Histopathological and docking studies. Bioorg Chem, 78(4): 103-114.

Mohamed A Abdelgawad, Rania B Bakr, Amany A Azouz (2018). Novel pyrimidine-pyridine hybrids: synthesis, cyclooxygenase inhibition, anti-inflammatory activity and ulcerogenic liability.  Bioorg Chem, 77: 339-348.

Eman KA Abdelall, Abdou O Abdelhamid, Amany A Azouz (2018). Corrigendum to" Synthesis and biological evaluations of new nitric oxide-anti-inflammatory drug hybrids". Bioorg Med Chem Lett, 28(4): 4358-4369.

Mohamed A Abdelgawad, Rania B Bakr, Ahmed O El-Gendy, Gehan M Kamel, Amany A Azouz, Syed Nasir Abbas Bukhari (2017). Discovery of a COX-2 selective inhibitor hit with anti-inflammatory activity and gastric ulcer protective effect. Future Med Chem; 9(16): 1899-1912.

Phoebe F Lamie, John N Philoppes, Amany A Azouz, Nesreen M Safwat (2017). Novel tetrazole and cyanamide derivatives as inhibitors of cyclooxygenase-2 enzyme: design, synthesis, anti-inflammatory evaluation, ulcerogenic liability and docking study. J Enzyme Inhib Med Chem; 32(1): 805-820.

Elshemy H.A., Abdelall E.K., Azouz A.A., Moawad A., Ali W.A., Safwat N.M. (2017). Synthesis, anti-inflammatory, cyclooxygenases inhibitions assays and histopathological study of poly-substituted 1,3,5-triazines: Confirmation of regiospecific pyrazole cyclization by HMBC. Eur J Med Chem, 127:10-21.

Bakr R.B., Azouz A.A. and Abdellatif K.R. (2016). Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1-phenylpyrazolo [3, 4-d] pyrimidine derivatives. J Enzyme Inhib Med Chem, 31(sup2):6-12.

Abdellatif K.R., Fadaly W.A., Azouz A.A. (2016).  Synthesis, Cyclooxygenase Inhibition, Anti-Inflammatory Evaluation,  and Ulcerogenic Liability of New 1,3,5-Triarylpyrazoline DerivativesPossessing a Methanesulfonyl Pharmacophore. Arch Pharm (Weinheim), 349(10):801-807.

Abdellatif K.R., Elshemy H.A. and Azoz A.A. (2015). 1-(4-Methane (amino) sulfonylphenyl)-3-(4-substituted-phenyl)-5-(4-trifluoromethylphenyl)-1H-2-pyrazolines/pyrazoles as potential anti-inflammatory agents. Bioorg chem, 63: 13-23.

Azouz A.A., Omar H.A., Abo-yousef A.M., El-Sherbiny G.A. and Abdel-Latif H.A. (2015). Different Protective Effects of Trimetazidine against Renal Ischemia/Reperfusion Injury in Rats. Br J Pharmacol Toxicol, 6 (3): 64-69.

PROJECTS:

1-    “Design, synthesis and biological evaluation of novel celecoxib derivatives”. Khaled R. Abdellatif, Heba A. Elshemy and Amany A. Azouz (2014). Project funded by Beni Suef University, Scientific Research Development Unit.

2-    “Studying the effect of nanoparticles loaded with combination of natural products having different modes of action for treatment of neurodegeneration”. Amany A. Azouz, Mohamed O. Mahmoud and Heba M. Aboud (2017). Project funded by Beni Suef University, Scientific Research Development Unit.

Master Title

Pharmacological study of the possible interactions between pantoprazole and some natural products on experimentally-induced gastric ulcer in rats

Master Abstract

Summary “Pharmacological study of the possible interactions between pantoprazole and some natural products on experimentally-induced gastric ulcer in rats” The present study investigated the possible protective effects of three natural products namely vinpocetine, marjoram oil and parsley oil in addition to pantoprazole, a reference standard antiulcerogenic agent, against experimentally-induced gastric ulcer. Gastric ulceration was induced by either pyloric ligation/indomethacin or ethanol. Five main sets of experiments were carried out. The first set was a pilot study carried out to choose suitable doses of indomethacin as well as the test drugs using pyloric ligation/indomethacin model. Indomethacin was administered intraperitoneally in doses of 10, 20, 30 and 40 mg/kg immediately after pyloric ligation to 48 h fasted rats. Test drugs were orally administered one hour before pyloric ligation. The dose levels of both pantoprazole and vinpocetine were 5, 10, 20 and 40 mg/kg, while that of marjoram oil and parsley oil were 25, 50, 75 and 100 mg/kg. The ulcerogenic effect of indomethacin and the antiulcerogenic potentials of test drugs were evaluated based on number of ulcers and ulcer index. Depending on the obtained results, the selected doses of indomethacin, pantoprazole, vinpocetine, marjoram oil and parsley oil were 30 mg/kg, 20 mg/kg, 20 mg/kg, 75 mg/kg and 75 mg/kg, respectively. The second set of experiments aimed at investigating the possible acute protective effect of the selected single dose of pantoprazole, vinpocetine, marjoram oil or parsley oil on pyloric ligation/indomethacin-induced gastric ulcer. The third set of experiments aimed at studying the possible subchronic antiulcerogenic potential of one week daily treatment with pantoprazole, vinpocetine, marjoram oil or parsley oil on pyloric ligation/indomethacin-induced gastric ulcer. The fourth set of experiments was carried out to evaluate the possible subchronic antiulcerogenic potential of one week daily treatment with pantoprazole (10 mg/kg) in combination with vinpocetine (20 mg/kg), marjoram oil (75 mg/kg) or parsley oil (75 mg/kg) on pyloric ligation/indomethacin-induced gastric ulcer. The fifth set of experiments aimed at investigating the possible acute protective effect of the selected single dose of pantoprazole, vinpocetine, marjoram oil or parsley oil on ethanol-induced ulceration. In this model, test drugs were administered orally one hour before administration of ethanol (70%, p.o.). The antiulcerogenic potentials of test drugs were evaluated based on number of ulcers, ulcer index, gastric juice volume and titratable acidity. The effects on oxidative stress biomarkers namely malondialdehyde (MDA), glutathione (GSH) and nitric oxide (NO) contents in gastric mucosa were evaluated in addition to superoxide dismutase (SOD) activity in blood. Gastric mucosal contents of histamine and mucus were also estimated. The findings of the present study can be summarized as follows:- A) Pyloric ligation/indomethacin model:- I. Acute treatment:- All test drugs protected against pyloric ligation/indomethacin-induced gastric ulcer as evidenced by significant reduction in ulcer number, ulcer index and MDA content as well as increased SOD activity in blood. In addition, all test drugs with the exception of parsley reduced gastric acidity and increased gastric mucosal NO content. II. One week daily treatment:- Daily administration of the test drugs for 7 days significantly reduced ulcer number, ulcer index, gastric juice volume, titratable acidity and MDA content. All test drugs significantly increased GSH, NO, SOD and mucus except in case of parsley where mucus content was not changed. Furthermore, vinpocetine and marjoram oil decreased gastric mucosal histamine content. III. Treatment with combination of pantoprazole (10 mg/kg) and individual test drugs daily for one week:- These combinations showed significant reduction in ulcer number, ulcer index, gastric juice volume, titratable acidity and MDA content as well as increase in gastric mucosal GSH and NO contents. Moreover, the combinations increased the action of pantoprazole. B) Ethanol model:- All test drugs protected against ethanol-induced gastric ulcer as evidenced by significant reduction in ulcer number and ulcer index as well as increased superoxide dismutase activity in blood. Marjoram oil only reduced MDA content. Vinpocetine, marjoram oil and parsley oil increased gastric mucosal GSH content. Pantoprazole only increased gastric mucosal NO content.

PHD Title

Possible protective effect of some vasodilators and certain anti-oxidant agent against experimentally-induced nephrotoxicity in rats

PHD Abstract

The present study aimed to investigate the possible protective effects of trimetazidine, sildenafil and coenzyme Q10 against experimentally-induced nephrotoxicity by either ischemia/reperfusion (I/R) or tacrolimus. To fulfill the aim of the present study, two different sets of experiments were used. I. Ischemia/reperfusion-induced nephrotoxicity: Bilateral renal ischemia was induced for 45 min followed by 24 h of reperfusion. Five groups of rats were used. Group I and II both administered 1% Tween 80 (p.o.) and served as sham-operated and I/R control groups, respectively. Group III, IV and V were orally administered trimetazidine (10 mg/kg), sildenafil (1 mg/kg) and coenzyme Q10 (10 mg/kg), respectively, as prophylactic treatment for two weeks. At the end of the treatment period, animals were subjected to I/R, then blood and kidney samples were collected. The nephroprotective potentials of the test agents were evaluated based on: 1. Relative kidney weight. 2. Renal function tests: blood urea nitrogen (BUN) and serum creatinine levels. 3. Electrolyte levels: serum calcium (Ca2+), sodium (Na+), potassium (K+) and chloride (Cl-). 4. Adenosine triphosphate content in kidney tissues. 5. Inflammatory biomarkers: kidney tumor necrosis factor-alpha (TNF-a) content and myeloperoxidase (MPO) activity. 6. Oxidative stress biomarkers: kidney malondialdehyde (MDA), glutathione (GSH) and total nitrite/nitrate (NOx) contents. 7. Histopathological examination of kidney sections. II. Tacrolimus-induced nephrotoxicity: Five groups of rats were used. Group I received 1% Tween 80 (p.o.) and served as normal control. Group II received tacrolimus (5 mg/kg, p.o.) for three weeks and served as tacrolimus control. Group III, IV and V received trimetazidine (10 mg/kg, p.o.), sildenafil (2 mg/kg, p.o.) and coenzyme Q10 (10 mg/kg, p.o.), respectively, for three weeks concomitantly with tacrolimus (5 mg/kg, p.o.). At the end of the treatment period, blood and kidney samples were collected. The nephroprotective potentials of the test agents were evaluated based on: 1. Renal function tests: BUN and serum creatinine levels. 2. Oxidative stress biomarkers: kidney MDA, GSH and NOx contents, as well as superoxide dismutase (SOD) activity. 3. Immunofluorescence analysis of inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) protein expression on kidney tissue sections. 4. Histopathological examination of kidney sections. Results of the present study can be summarized as follows: I. Protective effects of trimetazidine, sildenafil and coenzyme Q10 on ischemia/reperfusion-induced nephrotoxicity: 1. I/R significantly caused nephrotoxicity as manifested by a significant increase in relative kidney weight, BUN, serum creatinine and Na+ levels coupled with decrease in serum Ca2+, K+ and Cl- levels. 2. There was a significant decrease in kidney ATP content after I/R. 3. I/R resulted in increased kidney TNF-a content and MPO activity. 4. There was a significant increase in kidney MDA and NOx contents, while kidney GSH content was significantly reduced after I/R. 5. Histopathological examination of kidney sections from I/R control demonstrated the presence of severe hemorrhage, hematoma, vacuolar degeneration and coagulative necrosis in renal tubules. 6. Trimetazidine, sildenafil and coenzyme Q10 improved kidney function as evidenced by the reduction in BUN and serum creatinine levels. In addition, they ameliorated electrolyte disturbances associated with I/R injury. 7. All the test agents showed anti-ischemic activity as evidenced by restoration of kidney ATP content. 8. All the test agents showed anti-inflammatory activity as evidenced by reduced kidney TNF-a content and MPO activity. 9. All the test agents showed anti-oxidant activity as evidenced by reduced kidney MDA and restored GSH content. However, NOx content was significantly elevated higher than that of I/R control. 10. There was apparent improvement in histopathological features of kidney sections from trimetazidine, sildenafil and coenzyme Q10 treated groups as demonstrated by the regenerative changes in renal tubular epithelial cells. II. Protective effects of trimetazidine, sildenafil and coenzyme Q10 on tacrolimus-induced nephrotoxicity: 1. Tacrolimus administration for three successive weeks caused nephrotoxicity as manifested by increased BUN and serum creatinine levels. 2. Tacrolimus significantly increased kidney MDA and NOx contents, while kidney GSH content and SOD activity were significantly reduced. 3. Immunofluorescence analysis of kidney sections from tacrolimus control rats showed marked expression of iNOS and very weak expression of eNOS. 4. Histopathological examination of kidney sections from tacrolimus control rats demonstrated the presence of interstitial nephritis, vacuolation and collapse in renal tubules, in addition to endothelial swelling, vacuolation and hyalinosis in renal arterioles. 5. Trimetazidine, sildenafil and coenzyme Q10 significantly improved kidney function as evidenced by reduced BUN and serum creatinine levels. 6. All the test agents showed anti-oxidant activity as evidenced by reduced kidney MDA and restored GSH content and SOD activity. However, NOx content was significantly elevated higher than that of tacrolimus control in both trimetazidine and sildenafil treated rats. 7. Immunofluorescence analysis of kidney sections from trimetazidine, sildenafil and coenzyme Q10 treated rats showed weak expression of iNOS and marked expression of eNOS. 8. Histopathological examination of kidney sections from trimetazidine, sildenafil and coenzyme Q10 treated rats demonstrated absence of interstitial nephritis together with marked improvement in the structure of renal tubules and vasculature. Depending on the present results it can be concluded that: 1. Trimetazidine, sildenafil and coenzyme Q10 ameliorated renal damage induced by I/R or tacrolimus. 2. The protective effects of these agents are attributed to their anti-ischemic, anti-inflammatory and anti-oxidant properties. 3. These results suggest the therapeutic potential of these drugs in kidney transplantation to avoid graft rejection due to I/R or immunosuppressive drugs. Further clinical trials are needed to prove this claim.